"QuantityPath","Parameter","PKParameter","Value","ParameterPath"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_max",-0.255050951527095,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_max",0.272665677119562,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.0877127964790566,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.265017344244322,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","C_max",0.717806121207493,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","t_max",0,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","t_max",-0.166666666666667,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","t_max",0,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_tEnd",-0.658036599285532,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_tEnd",-0.142101846043505,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.464355180632146,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.666248721331105,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","C_tEnd",0.239491668949846,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_tEnd",-0.365982673466485,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_tEnd",0.14531721300049,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.248583760894866,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.456213009378286,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","AUC_tEnd",0.635222591621664,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_inf",-0.400491337568007,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_inf",0.129573623335071,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.254323546893216,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.457988043729724,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","AUC_inf",0.594353225491899,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","MRT",-0.246597693215911,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","MRT",-0.163778507968379,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.104914223737601,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.0923222742226498,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","MRT",-0.297333992078407,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Thalf",-0.359033608609222,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Thalf",-0.00933078011737706,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",0.107546637192447,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",0.176240934773225,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Thalf",-0.377071796097466,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","FractionAucLastToInf",-0.61654340783391,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","FractionAucLastToInf",-0.281628615903034,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.102405856300567,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.0313671563540043,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","FractionAucLastToInf",-0.731370208178693,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","CL",0.400617921894506,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","CL",-0.129689808360692,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.254350067102638,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.45770197269789,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","CL",-0.600509267137191,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vss",0.153758147672664,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vss",-0.293732481515959,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.14943282308451,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.365535800610767,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Vss",-0.899171823472165,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vd",0.0413083433586823,"Raltegravir|Lipophilicity"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vd",-0.139093821859926,"Raltegravir|Specific intestinal permeability (transcellular)"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.361955758359343,"Raltegravir-UGT1A9-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.634043501455333,"Raltegravir-UGT1A1-Kassahun 2007|In vitro Vmax for liver microsomes"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Vd",-0.979031040920114,"Applications|Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study|Weibull (lactose formulation)|Dissolution shape"
